XARELTO®: Efficacy profile in extended treatment and reduction in the risk of recurrence in deep vein thrombosis (DVT) and pulmonary embolism (PE)
SUPERIOR REDUCTION IN THE RISK OF RECURRENT DVT/PE*1
1.2% (13/1127) with XARELTO® versus 4.4% (50/1131) with aspirin
*After ≥6 months initial treatment.
Consistent reduction in DVT/PE in patients with an index PE event and in patients with a BMI ≥30 kg/m2 1,2
Lower rates of recurrent DVT/PE in patients with a PE index event
Nearly 50% of patients had a PE as
the index event in EINSTEIN CHOICE1
Lower rates of DVT/PE in patients with a BMI ≥30 kg/m2
Safety was not reported in patients with BMI ≥30 kg/m2.
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
†RRR calculated using 1 minus HR.
‡The decision regarding initiation setting should be based on the prescriber's clinical judgment.
BMI = body mass index; DOAC = direct oral anticoagulant; DVT = deep vein thrombosis; HR = hazard ratio; PE = pulmonary embolism; RRR = relative risk reduction; VKA = vitamin K antagonist; VTE = venous thromboembolism.